ASH 2019

Postrar presenterade vid ASH 2019.

7 december 2019

Titel: Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab

Poster: HORIZON (OP106) ASH Poster_WEB_07Dec2019

 

Titel: Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1

Poster: O-12-M1 Updated PFS-OS ASH Poster_WEB_07Dec2019

December 8, 2019:

Title: OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Poster: Amyloidosis ASH TiP Poster_WEB_08Dec2019

 

Title: ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI)

Poster: ANCHOR Phase 1-2 ASH Poster_WEB_08Dec2019

 

Title: In Vitro and in Vivo Activity of Melflufen in Amyloidosis

Poster: Melflufen in Amyloidosis_ASH poster_WEB_08Dec2019

 

Title: The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone

Poster: HORIZON Baseline QoL ASH Poster_WEB_08Dec2019